RXST Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -21.61% compared to RxSight's net margin of --. RxSight's return on equity of -10.39% beat Perspective Therapeutics's return on equity of --.

RxSight has a consensus price target of $20.45, signalling upside risk potential of 54.96%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 453.22%. Given that Perspective Therapeutics has higher upside potential than RxSight, analysts believe Perspective Therapeutics is more attractive than RxSight.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $37.9M, which are larger than Perspective Therapeutics quarterly revenues of --. RxSight's net income of -$8.2M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, RxSight's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 3.54x versus 16.51x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of -21.61% compared to RxSight's net margin of 12.62%. RxSight's return on equity of -10.39% beat Globus Medical's return on equity of 4.59%.

RxSight has a consensus price target of $20.45, signalling upside risk potential of 54.96%. On the other hand Globus Medical has an analysts' consensus of $84.00 which suggests that it could grow by 44.21%. Given that RxSight has higher upside potential than Globus Medical, analysts believe RxSight is more attractive than Globus Medical.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.324, suggesting its more volatile than the S&P 500 by 32.371%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $37.9M, which are smaller than Globus Medical quarterly revenues of $598.1M. RxSight's net income of -$8.2M is lower than Globus Medical's net income of $75.5M. Notably, RxSight's price-to-earnings ratio is -- while Globus Medical's PE ratio is 43.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 3.54x versus 3.22x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

PROCEPT BioRobotics has a net margin of -21.61% compared to RxSight's net margin of -35.77%. RxSight's return on equity of -10.39% beat PROCEPT BioRobotics's return on equity of -29.12%.

RxSight has a consensus price target of $20.45, signalling upside risk potential of 54.96%. On the other hand PROCEPT BioRobotics has an analysts' consensus of $76.88 which suggests that it could grow by 44.94%. Given that RxSight has higher upside potential than PROCEPT BioRobotics, analysts believe RxSight is more attractive than PROCEPT BioRobotics.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PROCEPT BioRobotics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PROCEPT BioRobotics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. PROCEPT BioRobotics pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $37.9M, which are smaller than PROCEPT BioRobotics quarterly revenues of $69.2M. RxSight's net income of -$8.2M is higher than PROCEPT BioRobotics's net income of -$24.7M. Notably, RxSight's price-to-earnings ratio is -- while PROCEPT BioRobotics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 3.54x versus 11.31x for PROCEPT BioRobotics. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -21.61% compared to RxSight's net margin of -10.04%. RxSight's return on equity of -10.39% beat Xtant Medical Holdings's return on equity of -35.34%.

RxSight has a consensus price target of $20.45, signalling upside risk potential of 54.96%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 193.33%. Given that Xtant Medical Holdings has higher upside potential than RxSight, analysts believe Xtant Medical Holdings is more attractive than RxSight.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $37.9M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. RxSight's net income of -$8.2M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, RxSight's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 3.54x versus 0.68x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.